Evaluation of Serum Fibroblast Growth Factor Levels in Acute Ischemic Stroke

Year 2025, Volume: 6 Issue: 1, 11 - 15, 15.03.2025

Mustafa Şen , Şahidin Şen , Süber Dikici , Handan Ankaralı , Hilmi Demirin

Abstract

Introduction: Stroke is a leading cause of death worldwide and remains very difficult to treat. Stroke results in brain damage through a cascade of events, including inflammatory responses and apoptosis. Serum basic fibroblast growth factor (bFGF) promotes the survival of nerve cells, stimulates new vessel formation, mesodermal remodeling, cell division, and cell migration, and accelerates wound healing. In this study, we evaluated serum bFGF levels in patients with ischemic stroke and examined the relationship between the clinical status of ischemic stroke patients and the control group.

Methods: We prospectively evaluated 96 patients (38 female and 58 male) admitted to our Neurology Clinic between February 2012 and October 2012, whose diagnosis of ischemic stroke was confirmed within 24 h after the onset of ischemic stroke. The control group comprised 48 age- and sex-matched healthy volunteers (32 female and 16 male) without vascular risk factors. the initial neurologic evaluation was performed using the National Institutes of Health Stroke Scale (NIHSS) to determine the severity of the stroke, and blood samples were obtained from all patients included in the study within 24 h from the onset of stroke to measure serum bFGF levels. These data were compared with data from control subjects.

Results: Serum bFGF levels of the ischemic stroke patients and the control group were 6.6±8.8 pg/ml and 4.6±4.3 pg/ml, respectively. A significant difference was noted between serum bFGF levels of both ischemic stroke patients and control subjects (p=0.005). Serum bFGF levels did not correlate significantly with NIHSS scores of patients with ischemic stroke (p>0.05).

Conclusions: We found that serum bFGF levels were significantly increased after acute ischemic stroke. The increase in serum bFGF levels in ischemic stroke patients may be a protective response to reduce brain damage.

Keywords

basic fibroblast growth factor, intracerebral ischemia, angiogenesis, acute ischemic stroke

Akut İskemik İnmede Serum Fibroblast Büyüme Faktörü Düzeylerinin Değerlendirilmesi

Abstract

Giriş: İnme, dünya çapında önde gelen bir ölüm nedenidir ve tedavisi hala çok zordur. İnme, inflamatuar yanıtlar ve apoptozis de dahil olmak üzere bir dizi olay yoluyla beyin hasarına neden olur. Serum bazik fibroblast büyüme faktörü (bFGF), sinir hücrelerinin hayatta kalmasını destekler, yeni damar oluşumunu, mezodermal yeniden şekillenmeyi, hücre bölünmesini ve hücre göçünü uyarır ve yara iyileşmesini hızlandırır. Bu çalışmada, iskemik inmeli hastalarda serum bFGF düzeylerini değerlendirdik ve iskemik inmeli hastaların klinik durumu ile kontrol grubu arasındaki ilişkiyi inceledik.

Yöntemler: Şubat 2012 ile Ekim 2012 arasında Nöroloji Kliniğimize başvuran ve iskemik inme tanısı iskemik inmenin başlangıcından sonraki 24 saat içinde doğrulanan 96 hastayı (38 kadın ve 58 erkek) prospektif olarak değerlendirdik. Kontrol grubu, vasküler risk faktörleri olmayan 48 yaş ve cinsiyete eşleştirilmiş sağlıklı gönüllüden (32 kadın ve 16 erkek) oluşuyordu. İlk nörolojik değerlendirme, felcin şiddetini belirlemek için Ulusal Sağlık Enstitüleri İnme Ölçeği (NIHSS) kullanılarak yapıldı ve çalışmaya dahil edilen tüm hastalardan, serum bFGF seviyelerini ölçmek için inmenin başlangıcından itibaren 24 saat içinde kan örnekleri alındı. Bu veriler, kontrol deneklerinden alınan verilerle karşılaştırıldı.

Bulgular: İskemik inme hastalarının ve kontrol grubunun serum bFGF seviyeleri sırasıyla 6,6±8,8 pg/ml ve 4,6±4,3 pg/ml idi. Hem iskemik inme hastalarının hem de kontrol deneklerinin serum bFGF seviyeleri arasında anlamlı bir fark kaydedildi (p=0,005). Serum bFGF seviyeleri, iskemik inme hastalarının NIHSS puanlarıyla anlamlı bir şekilde ilişkili değildi (p>0,05).

Sonuç: Akut iskemik inmeden sonra serum bFGF seviyelerinin anlamlı şekilde arttığını bulduk. İskemik inme hastalarında serum bFGF düzeylerindeki artış beyin hasarını azaltmak için koruyucu bir yanıt olabilir.

Keywords

temel fibroblast büyüme faktörü, intraserebral iskemi, anjiyogenez, akut iskemik inme

References

• Campbell BCV, Khatri P. Stroke. Lancet. 2020; 396(10244):129-42.
• Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke. Nat Rev Dis Primers. 2019; 5(1):70.
• Stinear CM, Lang CE, Zeiler S, et al. Advances and challenges in stroke rehabilitation. Lancet Neurol. 2020;19(4):348-60.
• Chen J, Zhang X, Liu X, et al. Ginsenoside Rg1 promotes cerebral angiogenesis via the PI3K/Akt/mTOR signalling pathway in ischemic mice. Eur J Pharmacol. 2019; 856.
• Beck H, Plate KH. Angiogenesis after cerebral ischemia. Acta Neuropathol. 2009; 117(5):481-96.
• Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011; 149(2):121-30.
• Matkar PN, Ariyagunarajah R, Leong-Poi H, et al. Friends Turned Foes: Angiogenic Growth Factors Beyond Angiogenesis. Biomolecules. 2017; 7(4):74.
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235-53.
• Klimaschewski L, Claus P. Fibroblast Growth Factor Signalling in the Diseased Nervous System. Mol Neurobiol. 2021; 58(8):3884-902.
• Zhu H, Zhang Y, Zhong Y, et al. Inflammation-mediated angiogenesis in Ischemic Stroke. Front Cell Neurosci. 2021; 15:652647.
• Hu HW, Li XK, Zheng RY, et al. bFGF expression mediated by a hypoxia-regulated adenoviral vector protects against PC12 cell death induced by serum deprivation. Biochem Biophys Res Commun 2009; 390(1):115-20.
• Lanfranconi S, Locatelli F, Corti S, et al. Growth factors in ischemic stroke. J Cell Mol Med. 2011; 15(8):1645-87.
• Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches. Cerebrovasc Dis. 2004;17 Suppl 1:153-66.
• Bogousslavsky J, Victor SJ, Salinas EO, et al. European-Australian Fiblast (Trafermin) in Acute Stroke Group Fiblast (trafermin) in acute stroke: results from the European-Australian phase II/III safety and efficacy study. Cerebrovasc Dis. 2002; 14:239–51.
• Huailian Guo, Li Huang, Min Cheng, et al. Serial measurement of serum basic fibroblast growth factor in patients with acute cerebral infarction. Neuroscience Letters 393 (2006) 56–59.
• Lin L, Wang Q, Qian K, et al. bFGF Protects Against Oxygen Glucose Deprivation/Reoxygenation-Induced Endothelial Monolayer Permeability via S1PR1-Dependent Mechanisms. Mol Neurobiol. 2018; 55(4):3131-3142.
• Dordoe C, Chen K, Huang W, et al. Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke. Front Pharmacol. 2021; 12:671131.
• Golab-Janowska M, Paczkowska E, Machalinski B, et al. Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients. Curr Neurovasc Res. 2019 ;16(1):19-26.
• Zimering MB, Anderson RJ, Ge L, et al. Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism 2011; 60(2):284-91.
• Issa R, AlQteİSKat A, Mitsios N, et al. Expression of basic fibroblast growth factor mRNA and protein in the human brain following ischaemic stroke. Angiogenesis 2005; 8(1):53-62.
• Lee S, Song IU, Na SH, et al. Association Between Long-term Functional Outcome and Change in hs-CRP Level in Patients With Acute Ischemic Stroke. Neurologist. 2020;25(5):122-25.